Aurora A has multiple key functions in tumor initiation and progression and is overexpressed in many cancers. Several ongoing clinical trials are assessing the unique therapeutic potential of Aurora-based targeted therapy, but several severe adverse events such as hematopoietic toxicity have been observed in the early-phase clinical trials because Aurora A is also involved in normal cells proliferation process. The strategy to develop tumor-specific inhibition of this target may be an alteration for the treatment of Aurora A overexpression tumors. In this study, we developed a novel tumor-specific RNA interference adenovirus system targeting Aurora A by using stathmin promoter and investigated the effects of it on the proliferation, apoptosis and chemotherapy sensitivity in human breast carcinoma cells both in vitro and in vivo. The results showed that treatment of human breast carcinoma cells (SK-BR-3 and MDA-MB-231) by Aurora A short hairpin RNA (shRNA) driven by stathmin gene promoter not only inhibited the cells proliferation, but also enhanced the chemosensitivity to paclitaxel via downregulation of Aurora A mRNA and protein expression, which further decreased the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression. Furthermore, there were no obvious phenotypes changes observed in normally differentiated epithelial cells of MCF210. Therefore, stathmin promoter-driving Aurora A shRNA adenoviral system may have potential use, with targeted tumor gene silencing effect and as adjuvant tumorspecific therapy method, in the treatment of human breast carcinomas.
Introduction
Breast carcinoma is one of the most common malignancies affecting women around the world and one in seven women is predicted to develop invasive breast cancer during their lifetime. Current therapeutic standards for breast cancer involve surgical resection of the tumor supplemented with radiation therapy and chemotherapy. 1 Cytotoxic drugs and hormone-blocking therapeutics are the most often used chemotherapeutics, generally chosen for their effects on cell growth and apoptosis. Conventional chemotherapy regimens for the treatment of breast carcinoma have limited efficacy for their significant toxicity in the body. 2 Generation of new therapeutic agents targeting carcinogenesis signal pathway have the potential to improve survival in populations that do not respond well to conventional therapies. Aurora A was discovered in a screen for Drosophila mutations affecting the poles of the mitotic spindle function. 3 The Aurora kinases regulate cell cycle transit from G2 through to cytokinesis. 4, 5 There are three mammalian aurora kinase genes, encoding Aurora A, B and C, which may have diverged from a single gene present in yeast.
Aurora A is localized on duplicated centrosomes and spindle poles during mitosis and is required for the timely entry into mitosis and proper formation of a bipolar mitotic spindle by regulating centrosome maturation, separation and microtubule nucleation activity. 6 In contrast, Aurora B is a chromosomal passenger protein, which is, together with INCENP, borealin and survivin, part of the chromosomal passenger complex. 7 Aurora kinase family members generated great interest after their overexpression and amplification was reported in a number of tumors. [8] [9] [10] Their overexpression and association with genetic instability in tumors have made them the focus of drug discovery. Owing to their involvement in a wide range of cell cycle events (for example, centrosome function, mitotic entry, kinetochore function, spindle assembly, chromosome segregation, microtubule dynamics, spindle checkpoint function and cytokinesis), they attracted a lot of attention from pharmaceutical companies to develop potential inhibitors against them. 11, 12 Extensive efforts have been made to develop inhibitors for Aurora A and Aurora B, and several highly potent inhibitory compounds have been identified. But there are still some concerns on these inhibitors about the side effects that will affect efficacy and toxicity profiles, and several severe adverse events such as hematopoietic toxicity have been observed in the early-phase clinical trials because Aurora A is also involved in normal cells proliferation process. The strategy to develop tumor-specific targeted inhibition regimen for Aurora A is urgently needed.
In the present report, we developed a novel tumorspecific short hairpin RNA (shRNA) adenovirus system targeting Aurora A directly under the control of stathmin promoter. Followingly, we detected the reduced expression of Aurora A, and we observed that the recombinant adenovirus-infected tumor cells showed a significant enhancement in chemosensitivity to paclitaxel besides a marked proliferation inhibition and apoptosis induction but spared the normal control cells. Taken together, our experimental data provided evidences of the potential use of stathmin promoter-driving shRNA targeting Aurora A as adjuvant tumor-specific therapy method for human breast carcinomas.
Materials and methods

Cell lines and cell culture
Human breast carcinoma cell lines (SK-BR-3 and MDA-MB-231), normal human mammary epithelial cell line (MCF210) and HEK293 cell line were purchased from Cell Center of Fourth Military Medical University and cultured in RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco), 4 mM glutamine, 100 units ml -1 penicillin and 100 mg ml -1 streptomycin. All cells were maintained at 37 1C with 5% CO 2 .
Stathmin mRNA expression detection and stathmin promoter luciferase assay To ensure that the stathmin promoter is specifically activity in breast carcinoma cells but not in normally differentiated cells, we first analyzed the expression of stathmin mRNA in both breast carcinoma cells and normal epithelial cells by semi-quantitative reverse transcriptase (RT)-PCR as described before. 13 Then the transcriptional activity of the stathmin promoter in breast carcinoma cells and normal epithelial cells were determined by the luciferase reporter plasmids as described by our laboratory previously. 13 Following plasmid vectors were used: a negative control (pGL3-basic), a positive control of cytomegalovirus (CMV) promoter (pGL3-CMV-luc) and the stathmin promoter plasmid (pGL3-sta-luc).
Stathmin promoter-driving Aurora A shRNA adenovirus preparing To prepare stathmin promoter-driving Aurora A shRNA adenovirus, we first constructed stathmin promoterdriving shRNA shuttle plasmid. The 451 bp stathmin core promoter fragment gene (Gene bank: AL033528) was amplified by PCR method to introduce XbalI and EcoRI enzyme sites by using our previously obtained stathmin promoter plasmid as template. 13 The primers were as follows: forward, 5
0 -GCCTCTAGACTCGAGA ATGGGGAGCTGGTTCGGA-3 0 ; reverse, 5 0 -GCCGAA TTCCTGCAGCAGGGGGTCGCTGCCACGG-3 0 (the underlined alphabets denote enzyme sites sequences). PCR amplification was performed as follows: 94 1C for 3 min; 94 1C for 40 s, 58 1C for 40 s, 72 1C for 90 s (35 cycles); 72 1C for 10 min. The PCR product was then inserted into the XbaI and EcoRI site of pDC315 shuttle plasmid to replace the CMV promoter and the recombinant shuttle plasmid was named as pDC315-sta. Then, shRNA against Aurora A gene (shAu: 5-AUGCCCUCUCUUACUGU CA-3) was designed as described by Tong et al 14 and inserted into pDC315-sta between NheI and BamHI enzyme sites, a scramble shRNA (5 0 -UUCUCCGAACG UGUCACGU-3 0 ) was used as negative control. The recombinant vectors were named as pDC315-sta-shAu and pDC315-sta-NC, respectively, and confirmed by both restriction endonuclease digestion analysis and DNA sequencing. The recombinant shuttle plasmids were then co-transfected with the packaging plasmid pBHGlox-E1,3Cre into HEK293 cells using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocols. After homologous recombination in HEK293 cells, the stathmin promoter-driving Aurora A shRNA or scramble shRNA adenoviruses were obtained and named as Ad-sta-shAu and Ad-sta-NC.
Adenovirus titer in plaque-forming units (pfu) was determined by plaque formation assay following infection of HEK293 cells. The multiplicity of infection was defined as the ratio of the total number of pfu to the total number of cells that were infected. We titrated adenovirus from duplicate samples in order to confirm the reproducibility of the experiments and the virus titers could reach 1.5 Â 10 9 and 1.3 Â 10 9 pfu ml -1 , respectively.
Recombinant Aurora A shRNA adenovirus infection SK-BR-3 and MDA-MB-231 cells were plated into six-well plates the day before infection at a seeding density of 5 Â 10 4 cells per well and maintained until the cells reached to 70-80% confluence. The culture medium was discarded and the cells were infected with different recombinant adenoviruses of Ad-sta-shAu and Ad-sta-NC at multiplicities of infection ranging from 10 to 300, multiplicity of infection ¼ 50 group was selected for further functional assay after detection of Aurora A knockdown effect by PCR method. The cells with no adenoviruses infection were used as blank control. After incubating for 48 h, the cells were washed, trypsinized and collected for future use. 
RT-PCR analysis
TdT-mediated dUTP nick end labeling (TUNEL) assay
The recombinant adenoviruses infected cells and blank control cells were seeded, respectively, in 100 mm culture plate in which coverslip was put previously, then the cells were collected after 72-h incubation. For tumor samples, frozen sections of xenograft tumor were prepared using tumor samples stored in liquid nitrogen. Both cultured cells and tumor tissue samples were determined by TUNEL apoptosis detection kit following the manufacturer's instruction (Keygen Biotech, Nanjing, China).
In vitro and in vivo chemotherapy assay In order to determine the effect of Ad-sta-shAu on chemosensitivity in vitro, the recombinant adenoviruses infected cells and blank control cells were treated with paclitaxel (Invitrogen) for different concentrations of 4.5, 9.0, 22.5, 45 and 90 mg ml -1 . Chemosensitivity was evaluated by MTT analysis and apoptosis detection assay. IC50 of paclitaxel was determined by MTT method. The cell survival value index was calculated as:
The cell apoptosis fraction was calculated as: apoptosis rate ¼ (apoptotic cell number)/(total cell number) Â 100%. Followingly, in vivo chemosensitivity to paclitaxel was tested in the mouse model by subcutaneous injection of SK-BR-3 cells into 8-week-old female athymic nude mice. When B100 mm 3 tumors were observed, mice were randomly selected for treatment with PBS, Ad-sta-NC, Ad-sta-shAu, Ad-sta-shAu plus paclitaxel, Ad-sta-NC plus paclitaxel and paclitaxel only. Each group consisted of 10 mice. Mice were given recombinant adenoviruses by intra-tumor injection of 1 Â 10 9 pfu (in 100 ml of PBS) of the indicated adenovirus once a day for the first week, then thrice per week until the endpoint of chemotherapy. From the second week, respective group of mice was treated with paclitaxel (10 mg kg -1 ; 3 times a week by intravenous injection), or 0.1 ml PBS. The length and width of the subcutaneous tumors as well as the mouse weight were measured every 3 days with calipers. The tumor volume (mm 3 ) was calculated with the following formula: a 2 b/2, where a is the short diameter (mm) and b is the long diameter (mm). The average tumor size were expressed as mean ± s.d. (n ¼ 10). After the mice were killed, the tumors were weighed and then incubated in formalin or frozen in liquid nitrogen. Animal experiments were performed in terms of medicine institutional guidelines of Fourth Military Medical University.
Statistical evaluations
All statistical analyses were performed by using SPSS17.0 (IBM, Chicago, IL). Data were expressed as mean ± s.d. Comparisons among all groups were performed with the one-way analysis of variance test and Student-NewmanKeuls method. Differences were considered significant at Po0.05.
Results
Stathmin gene expression and promoter activity detection It has been reported that stathmin gene is overexpressed in most of malignant tumor cells but not in normally differentiated cells, which is key factors for our experiment design. We first confirmed the differences of stathmin gene expression between breast carcinoma cell lines and normal epithelial cell line by RT-PCR method. As shown in Figure 1a , stathmin gene mRNA was expressed at high levels in both of the two breast cancer cell lines (MDA-MB-231 and SK-BR-3) but not detected in normal cell lines (MCF210). Then, we tested stathmin promoter activity by transient transfection of luciferase reporter vectors into the three different cells. The activity of the CMV promoter in each cell line was considered as positive control. As shown in Figure 1b , the stathmin promoter demonstrated high transcriptional activity in SK-BR-3 and MDA-MB-231 cells, but showed nearly background level of transcriptional activity in MCF210 cells.
Stathmin promoter-driving Aurora A shRNA adenovirus preparing To prepare Stathmin promoter-driving Aurora A shRNA adenovirus, we first constructed a stathmin promoterdriving shRNA shuttle plasmid by using a 451 bp stathmin core promoter fragment gene to replace the CMV promoter of pDC315 shuttle plasmid. As shown in Figure 2a , the recombinant shuttle plasmid had correct sequence and was named pDC315-sta. Then, the Aurora A shRNA and scramble shRNA were inserted into pDC315-sta vector between NheI and BamHI enzyme sites downstream of stathmin promoter, respectively, to form pDC315-sta-shAu and pDC315-sta-NC. Co-transfection of the pDC315-sta-shAu or pDC315-sta-NC with pBHGloxE1,3Cre packaging plasmid into HEK293 cells successfully propagated the recombinant adenovirus virion of Ad-sta-shAu and Ad-sta-NC. The virus titers were 1.5 Â 10 9 and 1.3 Â 10 9 pfu ml -1 , respectively. ) and p-Akt (ser 473 ) in these two cells obviously decreased by 2.8-, 4.2-folds and 3.1-, 5.0-folds, respectively, Po0.05; and these protein expression levels in SK-BR-3/Ad-sta-NC and MDA-MB-231/Ad-sta-NC cells showed no significant differences (P40.05).
Ad-sta-shAu specifically inhibited breast carcinoma cells growth in vitro In this experiment, cell proliferations of different recombinant adenoviruses treated breast carcinoma cells were monitored by MTT assay for 72 h. The cell viability curve (Figure 4a) showed that the proliferation of Ad-sta-shAuinfected tumor cells was obviously inhibited in a timedependent manner, and the highest inhibitory rate was 49.88±3.6% and 51.67±4.01%, respectively, on 72 h (Po0.05). All these data further confirmed the tumorspecific growth inhibition effect of stathmin promoterdriving Aurora A shRNA adenovirus system. 
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Ad-sta-shAu reduced colony formation potential in vitro To further investigate the effect of Ad-sta-shAu on tumor cells growth ability in vitro, we performed colony formation assay with different recombinant adenoviruses treated cells, respectively. The mean values±s.d. from three determinations are shown in Figure 4b . As expected from the results of MTT assay, the number of colonies in the SK-BR-3/Ad-sta-shAu and MDA-MB-231/Adsta-shAu cell groups (averaged colony number ¼ 158 and 162, respectively) was significantly reduced (Po0.05) compared with uninfected cell group, SK-BR-3/Adsta-NC cell group and MDA-MB-231/Ad-sta-NC cell group.
Ad-sta-shAu-induced cell cycle arrest of breast carcinoma cells
To confirm that the Ad-sta-shAu-mediated cell growth inhibition was the result of cell cycle arrest, we conducted cell cycle analysis of recombinant adenoviruses treated breast carcinoma cells by flow cytometry. As shown in Figure 5 , The percentage of G2/M phase in SK-BR-3/ Ad-sta-shAu and MDA-MB-231/Ad-sta-shAu cells increased by 23.27 ± 1.8%, and 30.82 ± 2.1%, respectively (Po0.05), but there were no obvious cell cycle arrest observed in SK-BR-3/Ad-sta-NC and MDA-MB-231/Adsta-NC cells compared with uninfected cells. These results further showed that the stathmin promoter-driving RNA interference-mediated specific knockdown of Aurora A induced strong inhibition of breast carcinoma cell growth in vitro.
Ad-sta-shAu specifically induce breast carcinoma cells apoptosis To further investigate the effects of Ad-sta-shAu on cell apoptosis, flow cytometry analysis and TUNEL assay were performed. Flow cytometry detection (Figure 6a ) showed that apoptosis percentage (Sum of Q2 plus Q4) of SK-BR-3/Ad-sta-shAu and MDA-MB-231/Ad-sta-shAu cells was obviously increased by 22.59±1.04% and 25.36 ± 2.2%, respectively (Po0.05), but no significant differences were observed in untransfected cells (blank) and Ad-sta-NC-treated cells. TUNEL assay results (Figure 6b ) showed that compared with blank parental cells and Ad-sta-NC-treated cells, Ad-sta-shAu-treated cells demonstrated a highly increasing dark brown-positive signal located in the nucleus, and the apoptotic rates of the Aurora A-downregulated SK-BR-3 and MDA-MB-231 cells were significantly higher than those of controls cells. These results further confirmed that Ad-sta-shAu could efficiently induce breast carcinoma cells apoptosis via downregulating Aurora A expression.
Ad-sta-shAu inhibited xenograft tumor growth and enhanced chemosensitivity of breast carcinoma cells in vitro and in vivo To eventually evaluate the therapeutic potential of Adsta-shAu adenovirus, we investigated the in vitro chemosensitivity enhancing effects of Aurora A shRNA on paclitaxel both in vitro and in vivo.
For in vitro chemosensitivity assay, Ad-sta-shAuinfected and -uninfected SK-BR-3 and MDA-MB-231 cells were determined by MTT assay (data not shown) (Figure 7c) .
In view of these findings in vitro, we tested the efficacy of Ad-sta-shAu as an in vivo therapy regimen and chemosensitizing strategy in a nude mouse xenograft model. After 5 weeks of treatment with PBS, Ad-sta-NC, Ad-sta-shAu, Ad-sta-NC plus paclitaxel, Ad-sta-shAu plus paclitaxel or Ad-sta-shAu downregulated Aurora A expression, blocked Aurora A pathway and induced apoptosis in xenograft tumor cells In order to confirm that the xenograft tumor growth inhibition effect was directly the result of Aurora A downregulation by Ad-sta-shAu, intracellular expression of Aurora A, p-BRCA1, p-Akt, cleaved caspase 3 and Bax as well as tumor cell apoptosis were detected. The results showed that the cleaved caspase 3 (Asp 175 ) and Bax proteins were significantly increased while p-BRCA1 (ser 308 ) and p-Akt (ser 473 ) expressions were obviously decreased in SK-BR-3 xenograft tumors treated with Adsta-shAu compared with control groups (Figure 8d) , as expected in the in vitro results. TUNEL assay result (Figure 8c) showed that Ad-sta-shAu could efficiently induce SK-BR-3 xenograft tumor cells apoptosis as indicated by dark brown-positive signal located in the tumor cell nucleus. All these results further confirmed the therapeutic potential of Ad-sta-shAu in the treatment of breast carcinomas.
Discussion
Breast cancer is the most common malignancy in females affecting around 1.3 million women worldwide each year and causing about 460 000 deaths annually. 15 Despite significant advances in early detection and steady progress in the treatment with systemic agents, most breast cancers develop resistance to drugs. In recent years, understanding of the underlying biological mechanisms of carcinogenesis and the altered molecular events has led to the identification of novel molecular targets and development of targeted therapies. Mitosis, the process by which a eukaryotic cell separates a complete copy of its duplicated genome into two identical sets in two daughter cells, is an extremely complex and tightly regulated process. 16 Central players in the mitotic process are the microtubules forming the mitotic spindle as well as the centrosome. 17 Defects in mitotic signaling pathways might lead to unrestrained growth, one of the hallmarks of cancer cells. 18, 19 Aurora kinases are a family of protein kinases that have a key role in multiple stages of mitosis. 20, 21 Overexpression of Aurora kinases, particularly Aurora A, has been demonstrated in a number of solid tumors and hematological malignancies. 22, 23 Aurora A has an important role in centrosome maturation, spindle assembly, meiotic maturation and metaphase I spindle orientation. These kinases have become attractive small molecule targets for cancer therapeutics, with several inhibitors currently in early-phase clinical trials. [24] [25] [26] However, the clinical activity of the aurora kinase inhibitors in patients with solid tumors has been rather disappointing as Aurora A is also involved in normal cells proliferation process. 27 Neutropenia being the primary dose-limiting phase I toxicity in several studies suggests that these agents have collateral anti-proliferation toxicity on the bone marrow. Aurora kinase inhibitors induce polyploidy in normal mammary epithelial cell cultures, thus raising the issue of long-term clinical effects. 11 Thus, targeted downregulation and restrained blocking of aurora gene only in tumor cells is an alteration for the therapeutic strategy using this target in the treatment of human cancers.
In this study, we first developed an adenovirus shRNA system driven by tumor-specific promoter of stathmin gene promoter. Presently, the most commonly used shRNAs expressing plasmids utilize CMV promoter or RNA polymerase-III-based promoters, including the U6 and H1-RNA promoters. [28] [29] [30] [31] Although these promoters synthesize shRNA and elicit RNA interference efficiently, they are constitutively expressed in all cell types and are not tissue or cell-specific. Thus, the use of these promoters to drive shRNA expression in vivo would produce undesirable side effect. Recently, a Pol II promoter-based shRNA construct has been reported as an alternate method to drive shRNA expression. As some Pol II promoters have cell-or tissue-specific expression property, they can provide an attractive strategy for targeted gene silence in gene therapy to decrease the probability of cellular toxicity. Our laboratory has previously shown that stathmin gene promoter that belongs to Pol II promoter displayed high activity in human cancer cells but not in differentiated cells. 13 Our data and some of others' reports have also shown that livin or survivin promoter employed to drive therapeutic genes could achieve tumor-targeted gene therapeutic effect. 32, 33 Unfortunately, there have been few reports about using stathmin gene promoter to drive shRNA in the antitumor study.
The results from Figure 1a demonstrated that the stathmin mRNA expression was upregulated only in human breast carcinoma cell lines but not detected in human normal mammary epithelial cell line. Additionally, luciferase reporter system detection (Figure 1b) showed that the transcriptional activity of stathmin promoter displayed high efficacy and tumor specificity only in breast cancer cells, which confirmed that the stathmin promoter was a good candidate to be used in the targeted tumor gene therapy both in vitro and in vivo, and suggested that the stathmin gene promoter would find broad applications in breast cancer gene therapy. Further studies also showed that stathmin gene promoter-driving Aurora A shRNA adenovirus could efficiently block Aurora A expression only in breast cancer cells, which led to the proliferation inhibition and reduced ability of colony formation of breast cancer cells (as shown in Figure 4 ).
It has been reported that Aurora A is a key regulator of cell cycle, and Aurora A inhibitors can induce the cancer cell cycle arrested at G2/M phase and further lead to apoptosis of the cells. Our experiment results from flow cytometry analysis showed that the percentage of G2/M phase in Ad-sta-shAu-treated breast carcinoma cells significantly increased, while there were no obvious differences in Ad-sta-NC-treated breast carcinoma cells compared with the parental cells ( Figure 5 ). In addition, flow cytometry analysis and TUNEL assay confirmed that cell cycle arrest finally caused the cell apoptosis ( Figure 6 ).
It has recently been shown that Aurora A promotes cell survival and migration by phosphorylated (p) Akt activation, inhibition of Aurora A can increase proteolytic cleavage of procaspase-3 and bax/bcl-2 expression ratio. 26, 34 In cell cycle regulation, Aurora A binds to BRCA1, the breast cancer susceptibility gene encoding a protein of 1863 amino acids of nuclear phosphorprotein, and phosphorylates Ser308 of BRCA1, through which Aurora A regulate mitotic entry. 35 In order to confirm that Ad-sta-shAu exerted tumor cell proliferation inhibition and apoptosis induction were the direct effects of Aurora A downregulation, we performed western blot to detect these downstream effectors of Aurora A. As shown in Figure 2 , cleaved caspase 3 (Asp 175 ) proteins in SK-BR-3/Ad-sta-shAu and MDA-MB-231/Ad-sta-shAu cells significantly increased, while the expression of p-BRCA1 (ser 308 ) and p-Akt1 (ser 473 ) in these two cells obviously decreased; but these protein expression levels in SK-BR-3/Ad-sta-NC and MDA-MB-231/Ad-sta-NC cells showed no significant differences. These results further confirmed targeted therapeutic potential of stathmin promoter-driving Aurora A shRNA adenoviral system.
More importantly, the increased chemosensitivity of Ad-sta-shAu-treated breast carcinoma cells was also observed as shown in Figure 7 . These results indicated that Ad-sta-shAu could not only efficiently inhibit SK-BR-3 breast carcinoma xenograft tumors growth, but also had synergistic tumor growth inhibition and chemosensitivity effects in breast carcinoma therapy. All these results have perhaps built a fundamental basis for further therapeutic study of stathmin gene promoter-driving shRNA system in the cancer gene therapy.
In conclusion, we have for the first time showed that the tumor-specific downregulation Aurora A gene expression adenovirus system mediated by the stathmin promoter is especially useful in targeted breast cancer gene therapy. The combination of Ad-sta-shAu gene therapy and chemotherapy for human breast cancer cells can significantly enhance chemosensitivity both in vitro and in vivo by increasing apoptosis and reducing DNA repair ability. The results of this study provided further support for the strategy of stathmin gene promoter-driving shRNA adenovirus as a novel and useful strategy for the treatment of human breast cancer.
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